Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial.
Saved in:
| Title: | Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial. |
|---|---|
| Authors: | Cramer P; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany. Electronic address: paula.cramer@uk-koeln.de., Fürstenau M; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany., Robrecht S; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany., Giza A; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany., Zhang C; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany., Fink AM; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany., Fischer K; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany., Langerbeins P; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany., Al-Sawaf O; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany., Tausch E; Department of Internal Medicine III, Division of CLL, University Hospital Ulm, Ulm, Germany., Schneider C; Department of Internal Medicine III, Division of CLL, University Hospital Ulm, Ulm, Germany., Schetelig J; Department I of Internal Medicine, University Hospital Carl Gustav Carus, Dresden, Germany., Dreger P; Department V of Internal Medicine, University Hospital Heidelberg, Heidelberg, Germany., Böttcher S; Clinic for Internal Medicine III (Hematology, Oncology, Palliative Care), Rostock University Medical School, Rostock, Germany., Kreuzer KA; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany., Schilhabel A; Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany., Ritgen M; Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany., Brüggemann M; Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany., Kneba M; Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany., Stilgenbauer S; Department of Internal Medicine III, Division of CLL, University Hospital Ulm, Ulm, Germany., Eichhorst B; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany., Hallek M; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany. |
| Source: | The Lancet. Haematology [Lancet Haematol] 2022 Oct; Vol. 9 (10), pp. e745-e755. Date of Electronic Publication: 2022 Aug 18. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Multicenter Study |
| Journal Info: | Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 35988545 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Cramer+P%22">Cramer P</searchLink>; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany. Electronic address: paula.cramer@uk-koeln.de.<br /><searchLink fieldCode="AU" term="%22Fürstenau+M%22">Fürstenau M</searchLink>; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Robrecht+S%22">Robrecht S</searchLink>; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Giza+A%22">Giza A</searchLink>; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Zhang+C%22">Zhang C</searchLink>; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Fink+AM%22">Fink AM</searchLink>; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Fischer+K%22">Fischer K</searchLink>; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Langerbeins+P%22">Langerbeins P</searchLink>; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Al-Sawaf+O%22">Al-Sawaf O</searchLink>; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Tausch+E%22">Tausch E</searchLink>; Department of Internal Medicine III, Division of CLL, University Hospital Ulm, Ulm, Germany.<br /><searchLink fieldCode="AU" term="%22Schneider+C%22">Schneider C</searchLink>; Department of Internal Medicine III, Division of CLL, University Hospital Ulm, Ulm, Germany.<br /><searchLink fieldCode="AU" term="%22Schetelig+J%22">Schetelig J</searchLink>; Department I of Internal Medicine, University Hospital Carl Gustav Carus, Dresden, Germany.<br /><searchLink fieldCode="AU" term="%22Dreger+P%22">Dreger P</searchLink>; Department V of Internal Medicine, University Hospital Heidelberg, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Böttcher+S%22">Böttcher S</searchLink>; Clinic for Internal Medicine III (Hematology, Oncology, Palliative Care), Rostock University Medical School, Rostock, Germany.<br /><searchLink fieldCode="AU" term="%22Kreuzer+KA%22">Kreuzer KA</searchLink>; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Schilhabel+A%22">Schilhabel A</searchLink>; Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany.<br /><searchLink fieldCode="AU" term="%22Ritgen+M%22">Ritgen M</searchLink>; Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany.<br /><searchLink fieldCode="AU" term="%22Brüggemann+M%22">Brüggemann M</searchLink>; Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany.<br /><searchLink fieldCode="AU" term="%22Kneba+M%22">Kneba M</searchLink>; Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany.<br /><searchLink fieldCode="AU" term="%22Stilgenbauer+S%22">Stilgenbauer S</searchLink>; Department of Internal Medicine III, Division of CLL, University Hospital Ulm, Ulm, Germany.<br /><searchLink fieldCode="AU" term="%22Eichhorst+B%22">Eichhorst B</searchLink>; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Hallek+M%22">Hallek M</searchLink>; Department I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101643584%22">The Lancet. Haematology</searchLink> [Lancet Haematol] 2022 Oct; Vol. 9 (10), pp. e745-e755. <i>Date of Electronic Publication: </i>2022 Aug 18. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase II; Journal Article; Multicenter Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Ltd%22">Elsevier Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101643584 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2352-3026 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223523026%22">23523026 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Haematol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35988545 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/S2352-3026(22)00211-3 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: e745 Titles: – TitleFull: Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Cramer P – PersonEntity: Name: NameFull: Fürstenau M – PersonEntity: Name: NameFull: Robrecht S – PersonEntity: Name: NameFull: Giza A – PersonEntity: Name: NameFull: Zhang C – PersonEntity: Name: NameFull: Fink AM – PersonEntity: Name: NameFull: Fischer K – PersonEntity: Name: NameFull: Langerbeins P – PersonEntity: Name: NameFull: Al-Sawaf O – PersonEntity: Name: NameFull: Tausch E – PersonEntity: Name: NameFull: Schneider C – PersonEntity: Name: NameFull: Schetelig J – PersonEntity: Name: NameFull: Dreger P – PersonEntity: Name: NameFull: Böttcher S – PersonEntity: Name: NameFull: Kreuzer KA – PersonEntity: Name: NameFull: Schilhabel A – PersonEntity: Name: NameFull: Ritgen M – PersonEntity: Name: NameFull: Brüggemann M – PersonEntity: Name: NameFull: Kneba M – PersonEntity: Name: NameFull: Stilgenbauer S – PersonEntity: Name: NameFull: Eichhorst B – PersonEntity: Name: NameFull: Hallek M IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 10 Text: 2022 Oct Type: published Y: 2022 Identifiers: – Type: issn-electronic Value: 2352-3026 Numbering: – Type: volume Value: 9 – Type: issue Value: 10 Titles: – TitleFull: The Lancet. Haematology Type: main |
| ResultId | 1 |
